Arthur Bentlage

Mr. Arthur Bentlage

orcid

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 August 2020 in Science
Verified
Journal Article
Open access
PDF file
PBPhilip J. M. Brouwer
Philip J. M. Brouwer
TCTom G. Caniels
Tom G. Caniels
KSKarlijn van der Straten
Karlijn van der Straten
JSJonne L. Snitselaar
Jonne L. Snitselaar
YAYoann Aldon
Yoann Aldon
MGMarit van Gils
Marit van Gils
Sites of vulnerability in SARS-CoV-2: Antibodies that neutralize severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) could be an important tool in treating coronavirus disease 2019 (COVID-19). Brouwer et al. isolated 403 monoclonal antibodies from three convalescent COVID-19 patients. They show that the patients had strong immune responses against the viral spike protein, a complex that binds to receptors on the host cell. A subset of antibodies was able to neutralize the virus. Competition and electron microscopy studies showed that these antibodies target diverse epitopes on the spike, with the two most potent targeting the domain that binds the host receptor. Science , this issue p. 643

26 February 2021 in Science
Verified
Journal Article
Open access
PDF file
MLMads Delbo Larsen
Mads Delbo Larsen
EGErik L. de Graaf
Erik L. de Graaf
MSMyrthe E. Sonneveld
Myrthe E. Sonneveld
HPH. Rosina Plomp
H. Rosina Plomp
JNJan Nouta
Jan Nouta
Gestur VidarssonGestur Vidarsson
Gestur Vidarsson
A single sugar makes all the difference: Antibodies are divided into several classes based on their nonvariable tail (Fc) domains. These regions interact with disparate immune cell receptors and complement proteins to help instruct distinct immune responses. The Fc domain of immunoglobulin G (IgG) antibodies contains a conserved N-linked glycan at position 297. However, the particular glycan used at this position is highly variable. IgG lacking core fucosylation at this position initiates enhanced antibody-dependent cellular cytotoxicity by increased affinity to the Fc receptor FcRIIIa. Larsen et al. report that COVID-19 patients with severe symptoms have increased levels of anti–severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) IgG afucosylation compared with patients with mild disease. These findings suggest that treatment of COVID-19 patients with fucosylated anti–SARS-CoV-2 antibodies may circumvent pathologies associated with severe COVID-19. Science , this issue p. eabc8378

15 March 2021 in Journal of Clinical Investigation
Verified
Journal Article
Closed access
PDF file
NHNiels Heemskerk
Niels Heemskerk
MGMandy Gruijs
Mandy Gruijs
ATA. Robin Temming
A. Robin Temming
MHMarieke Heineke
Marieke Heineke
DGDennis Y. Gout
Dennis Y. Gout
MEMarjolein Van Egmond
Marjolein Van Egmond
Most clinically used anticancer mAbs are of the IgG isotype, which can eliminate tumor cells through NK cell–mediated antibody-dependent cellular cytotoxicity and macrophage-mediated antibody-dependent phagocytosis. IgG, however, ineffectively recruits neutrophils as effector cells. IgA mAbs induce migration and activation of neutrophils through the IgA Fc receptor (FcαRI) but are unable to activate NK cells and have poorer half-life. Here, we combined the agonistic activity of IgG mAbs and FcαRI targeting in a therapeutic bispecific antibody format. The resulting TrisomAb molecules recruited NK cells, macrophages, and neutrophils as effector cells for eradication of tumor cells in vitro and in vivo. Moreover, TrisomAb had long in vivo half-life and strongly decreased B16F10gp75 tumor outgrowth in mice. Importantly, neutrophils of colorectal cancer patients effectively eliminated tumor cells in the presence of anti-EGFR TrisomAb but were less efficient in mediating killing in the presence of IgG anti-EGFR mAb (cetuximab). The clinical application of TrisomAb may provide potential alternatives for cancer patients who do not benefit from current IgG mAb therapy.

4 January 2024 in Blood
Verified
Journal Article
Closed access
PDF file
SVSaskia van der Velden
Saskia van der Velden
TOThijs L. J. van Osch
Thijs L. J. van Osch
ASAmina Seghier
Amina Seghier
ABArthur Bentlage
Arthur Bentlage
JMJuk Yee Mok
Juk Yee Mok
RKRick Kapur
Rick Kapur
Transfusion-related acute lung injury (TRALI) is one of the leading causes of transfusion-related fatalities and, to date, is without available therapies. Here, we investigated the role of the complement system in TRALI. Murine anti–major histocompatibility complex class I antibodies were used in TRALI mouse models, in combination with analyses of plasma samples from patients with TRALI. We found that in vitro complement activation was related to in vivo antibody-mediated TRALI induction, which was correlated with increased macrophage trafficking from the lungs to the blood in a fragment crystallizable region (Fc)-dependent manner and that this was dependent on C5. Human immunoglobulin G 1 variants of the murine TRALI-inducing antibody 34-1-2S, either unable to activate complement and/or bind to Fcγ receptors (FcγRs), revealed an essential role for the complement system, but not for FcγRs, in the onset of 34-1-2S–mediated TRALI in mice. In addition, we found high levels of complement activation in the plasma of patients with TRALI (n = 53), which correlated with elevated neutrophil extracellular trap (NET) markers. In vitro we found that NETs could be formed in a murine, 2-hit model, mimicking TRALI with lipopolysaccharide and C5a stimulation. Collectively, this reveals a critical role of Fc-mediated complement activation in TRALI, with a direct relation to macrophage trafficking from the lungs to the blood and an association with NET formation, suggesting that targeting the complement system may be an attractive therapeutic approach for combating TRALI.

14 October 2022 in Nature Communications
Verified
Journal Article
Open access
PDF file
MBMaximilian Brinkhaus
Maximilian Brinkhaus
EPErwin Pannecoucke
Erwin Pannecoucke
EKElvera J. van der Kooi
Elvera J. van der Kooi
ABArthur Bentlage
Arthur Bentlage
NDNinotska I. L. Derksen
Ninotska I. L. Derksen
Gestur VidarssonGestur Vidarsson
Gestur Vidarsson
Binding to the neonatal Fc receptor (FcRn) extends serum half-life of IgG, and antagonizing this interaction is a promising therapeutic approach in IgG-mediated autoimmune diseases. Fc-MST-HN, designed for enhanced FcRn binding capacity, has not been evaluated in the context of a full-length antibody, and the structural properties of the attached Fab regions might affect the FcRn-mediated intracellular trafficking pathway. Here we present a comprehensive comparative analysis of the IgG salvage pathway between two full-size IgG1 variants, containing wild type and MST-HN Fc fragments, and their Fc-only counterparts. We find no evidence of Fab-regions affecting FcRn binding in cell-free assays, however, cellular assays show impaired binding of full-size IgG to FcRn, which translates into improved intracellular FcRn occupancy and intracellular accumulation of Fc-MST-HN compared to full size IgG1-MST-HN. The crystal structure of Fc-MST-HN in complex with FcRn provides a plausible explanation why the Fab disrupts the interaction only in the context of membrane-associated FcRn. Importantly, we find that Fc-MST-HN outperforms full-size IgG1-MST-HN in reducing IgG levels in cynomolgus monkeys. Collectively, our findings identify the cellular membrane context as a critical factor in FcRn biology and therapeutic targeting.

1 November 2017 in Gastroenterology
Verified
Journal Article
Closed access
FBFelicia M. Bloemendaal
Felicia M. Bloemendaal
ALAlon D. Levin
Alon D. Levin
MWManon E. Wildenberg
Manon E. Wildenberg
PKPim J. Koelink
Pim J. Koelink
BMBradford L. McRae
Bradford L. McRae
GGGisou Van Der Goot
Gisou Van Der Goot